5-(2-fluorophenyl)-2H-1,2,3-triazole-4-carbonitrile | 1352658-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(2-fluorophenyl)-2H-1,2,3-triazole-4-carbonitrile
• 英文别名: 5-(2-Fluorophenyl)-2H-1,2,3-triazole-4-carbonitrile；5-(2-fluorophenyl)-2H-triazole-4-carbonitrile
• CAS: 1352658-68-4
• 化学式: C₉H₅FN₄
• 分子量: 188.164
• InChiKey: ZCONVIFDAAMTFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氟苯甲醛 、 苯磺酰乙腈 在 sodium azide 作用下， 以 水 为溶剂， 反应 1.0h， 以95%的产率得到5-(2-fluorophenyl)-2H-1,2,3-triazole-4-carbonitrile
  参考文献：
  名称：

  串联Knoevenagel- [3 + 2]环加成消除反应：一锅合成4,5-二取代1,2,3-（NH）-三唑

  摘要：

  已发现叠氮化钠催化芳香醛和氰基化合物与活性亚甲基氢之间的Knoevenagel缩合反应，这已导致一锅法合成一锅法合成4,5-二取代1,2,3-（NH）-三唑的成功途径。通过Knoevenagel- [3 + 2]环加成-消除序列形成醛。在形成5-芳基-2 H -1,2,3-三唑-4-腈的衍生物中，发现该反应在水中有效地发生。

  DOI：

  10.1016/j.tetlet.2011.10.146

文献信息

• [EN] CYANOTRIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS CYANOTRIAZOLE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2015008872A1

  公开（公告）日：2015-01-22

  This invention relates to a cyanotriazole compound represented by the formula (1):, wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖，副作用较少，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病，糖耐量受损，胰岛素抵抗，糖尿病并发症，肥胖，血脂异常，肝脂肪变性，动脉粥样硬化和/或心血管疾病，以及那些受益于刺激能量消耗的疾病或疾病。
• CYANOTRIAZOLE COMPOUNDS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20160229816A1

  公开（公告）日：2016-08-11

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中有定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖症的副作用较小，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖症具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、脂肪肝、动脉粥样硬化和/或心血管疾病，以及那些从刺激能量消耗中受益的疾病或疾病。
• Cyanotriazole compounds
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10626095B2

  公开（公告）日：2020-04-21

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰三唑化合物： 其中各符号在说明书中定义，或其盐。该化合物或其盐可刺激柠檬酸循环活性和/或改善高血糖，且副作用小、安全性高，因此可用于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或紊乱、例如，糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、肝脂肪变性、动脉粥样硬化和/或心血管疾病，以及可从刺激能量消耗中获益的疾病或紊乱。
• Tandem Knoevenagel-[3+2] cycloaddition-elimination reactions: one-pot synthesis of 4,5-disubstituted 1,2,3-(NH)-triazoles
  作者：Thanasekaran Ponpandian、Shanmugam Muthusubramanian

  DOI：10.1016/j.tetlet.2011.10.146

  日期：2012.1

  found to catalyse Knoevenagel condensation between aromatic aldehyde and cyano compound with active methylene hydrogens and this has led to a successful route for the one pot synthesis of 4,5-disubstituted 1,2,3-(NH)-triazoles from aldehydes through Knoevenagel-[3+2]cycloaddition-elimination sequence. In the formation of 5-aryl-2H-1,2,3-triazole-4-carbonitrile derivatives, the reaction has been found

  已发现叠氮化钠催化芳香醛和氰基化合物与活性亚甲基氢之间的Knoevenagel缩合反应，这已导致一锅法合成一锅法合成4,5-二取代1,2,3-（NH）-三唑的成功途径。通过Knoevenagel- [3 + 2]环加成-消除序列形成醛。在形成5-芳基-2 H -1,2,3-三唑-4-腈的衍生物中，发现该反应在水中有效地发生。